and pdbqt
Thanks to their expanded interface with the target protein, peptide PROTACs demonstrate superior potency, higher selectivity, and reduced toxicity compared to low molecular weight compounds, especially when targeting proteins lacking well-defined binding pockets (Kargbo, 2019)
While they can offer antioxidant support and brighten surface-level pigmentation, their effects are limited compared to oral or injectable forms, as glutathione molecules struggle to penetrate deeply into skin layers
92 Therefore, targeting mild TBI with different types of antioxidants may be a viable approach to treatment
This data is valuable because it captures effects in broader populations than clinical trials, including people with comorbidities, those taking multiple medications, and those using doses or schedules that differ from trial protocols